8 results about "Cell ageing" patented technology

The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway. As a marketed drug, semaglutide has clear safety, a long half-life and high patient compliance, and has a significant clinical conversion prospect. The application breaks through the limitation that existing hormone replacement therapy and assisted reproductive technology can only treat symptoms or solve the problem of fertility, provides a first drug intervention strategy which can fundamentally delay the process of follicle depletion, and fills the blank in the field of ovarian aging treatment.

The application relates to application of a reagent for detecting expression levels of a PSIP1 gene or a coded protein LEDGF / p75 in preparation of a product for evaluating systemic lupus erythematosus disease activity, which makes up for the problems of insufficient sensitivity and specificity of existing evaluation indexes; the application also discloses a key role of the PSIP1 gene in a pathogenesis mechanism of systemic lupus erythematosus, and clearly shows the relationship between the PSIP1 gene in T cells and cell cycle arrest, cell aging and abnormal immune function, so as to provide a theoretical basis for target regulation of the PSIP1 to improve T cell function and delay or block disease progression; the application firstly proposes that the expression levels of the PSIP1 / LEDGF / p75 are detected to be used for evaluating systemic lupus erythematosus disease activity, auxiliary diagnosis, prognosis prediction and treatment effect monitoring, so as to provide a brand-new tool and direction for precise diagnosis, activity evaluation, prognosis judgment and future target treatment development of systemic lupus erythematosus.

The present application provides a composition with satiety and weight control and anti-aging, and a preparation method and application thereof. The composition comprises the following raw materials by weight: polysaccharide 11-13 parts, fiber powder 20-25 parts, highland barley powder 12-18 parts, compound powder 18-23 parts, pectin 4-8 parts, ganoderma lucidum powder 6-9 parts, and compound protein 8-12 parts, and relates to the technical field of satiety and weight control and anti-aging compositions. The composition can form an effect of hindering nutrient absorption or prolonging gastric emptying, increase the volume of intestinal contents to achieve satiety, thereby achieving the functions of well controlling weight gain and reducing body weight. In addition, the composition can activate the body's antioxidant enzyme system, improve the activity of superoxide dismutase (SOD), and reduce the content of malondialdehyde (MDA), thereby delaying cell aging and achieving the anti-aging effect.

The application relates to the technical field of pharmaceutical preparations, in particular to application of Thalia dealbata in inhibiting a PI3K / Akt / mTOR signal path to slow down animal cell aging, which finds that Thalia dealbata can delay body aging after being applied to an aging model, and can slow down the animal cell aging process by inhibiting the activity of the PI3K / Akt / mTOR signal path, and effectively improves the efficiency of Thalia dealbata in slowing down aging.

The present application relates to the field of microbial technology, and particularly relates to the application of AKK bacteria and products thereof in anti-aging and / or anti-oxidation. The preservation number of the AKK bacteria is CGMCC No. 20954, and the strain is preferably used in a pasteurized form. Through three kinds of zebrafish model experiments, it is proved that the strain can effectively improve cell aging, specifically, the telomere length is improved, the expression amount of anti-aging gene spns1 is enhanced, and the symptoms of muscle atrophy and cognitive impairment caused by aging are obviously improved. In particular, the minimum effective amount of the strain in the water body for feeding zebrafish is 250 μg / mL, and the minimum effective amount in the human body is 30 billion AFU per person per day. The present application provides a clear strain source and dosage basis for developing a multi-dimensional and systematic anti-aging functional composition.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

The application discloses application of methyl palmitate in preparation of a medicine for treating and / or preventing senility and related cognitive impairment, and belongs to the technical field of biological medicine. The application proves by a cell experiment that methyl palmitate can significantly inhibit D-galactose-induced SH-SY5Y cell senility, and effectively reduce the expression level of senility-related proteins P53 and P16. The application proves by a behavior experiment that methyl palmitate can significantly improve the cognitive index of a senility model mouse, shorten an escape latency, and effectively improve learning ability reduction, spatial memory decline and cognitive function impairment caused by senility. In addition, methyl palmitate can significantly enhance the long-term potentiation effect of the hippocampal CA1 region of the senility model mouse, and reverse senility-related synaptic transmission damage. The application discloses the application of methyl palmitate in resisting neural senility and improving senility-related cognitive impairment, and provides a new candidate molecule for preparing a medicine for treating neurodegenerative diseases.